You are cordially invited to attend a professional lecture

featuring

. Susan Scanland, MSN, APRN, BC-G

CEO & Founder Dementia Connection LLC - National Expert and Speaker on Alzheimers
Dementia Consultant - Riverside Nursing and Rehabilitation Taylor PA
University of Scranton - Department of Nursing

This promotional program is intended to educate healthcare practitioners on

NAMENDA XR® (memantine hydrochloride) and the treatment of moderate to severe dementia of the Alzheimer's type.

Tuesday, March 11, 2014 6:30 PM

Cooper's Seafood House
701 North Washington Avenue
Scranton,Pennsylvania 18509
570-346-6883

Please RSVP by Sunday, March 9, 2014

RSVP to your Forest Pharmaceuticals, Inc. representative, Keith Stiles

Email : keith.stiles@frx.com

Phone: 1-888-430-5227, Ext. 77272703

Mobile : 716-479-8359

Attendance is limited to active, state-licensed healthcare professionals. Attendees will be required to provide their license number at the program. This invitation is not extended to certain specialties.

Forest speaker programs adhere to applicable federal and state laws and regulations, including all disclosure requirements. This invitation is not extended to practitioners licensed in certain states and where otherwise prohibited by law.

Important Safety Information

Warnings and Precautions

- NAMENDA XR should be used with caution under conditions that raise urine pH (including alterations by diet, drugs and the clinical state of the patient). Alkaline urine conditions may decrease the urinary elimination of memantine, resulting in increased plasma levels and a possible increase in adverse effects.
- NAMENDA XR has not been systematically evaluated in patients with a seizure disorder.

Please see additional Important Safety Information on reverse side and accompanying full Prescribing Information.

Forest Pharmaceuticals, Inc.
Subsidiary of Forest Laboratories, Inc.

NAMENDA XR® (memantine hydrochloride) extended-release capsules are indicated for the treatment of moderate to severe dementia of the Alzheimer's type.

Important Safety Information (continued)

Contraindications

- NAMENDA XR is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation.

Adverse Reactions

- The most commonly observed adverse reactions seen in patients administered NAMENDA XR (28 mg/day) in a controlled clinical trial, defined as those occurring at a frequency of at least 5% in the NAMENDA XR group and at a higher frequency than placebo were headache (6% vs 5%), diarrhea (5% vs 4%), and dizziness (5% vs 1%).

Drug Interactions

- No drug-drug interaction studies have been conducted with NAMENDA XR, specifically. The combined use of NAMENDA XR with other NMDA antagonists (amantadine, ketamine, or dextromethorphan) has not been systematically evaluated and such use should be approached with caution.

Dosage and Administration

- The recommended starting dose of NAMENDA XR is 7 mg once-daily. The recommended target dose is 28 mg once-daily. The dose should be increased in 7 mg increments to 28 mg once-daily. The minimum recommended interval between dose increases is one week, and only if the previous dose has been well tolerated. The maximum recommended dose is 28 mg once-daily.

- It is recommended that a patient who is on a regimen of 10 mg twice daily of NAMENDA tablets be switched to NAMENDA XR 28 mg once-daily capsules the day following the last dose of a 10 mg NAMENDA tablet. There is no study addressing the comparative efficacy of these 2 regimens.

- It is recommended that a patient with severe renal impairment who is on a regimen of 5 mg twice daily of NAMENDA tablets be switched to NAMENDA XR 14 mg once-daily capsules the day following the last dose of a 5 mg NAMENDA tablet.

Special Populations

- NAMENDA XR should be administered with caution to patients with severe hepatic impairment.

- A target dose of 14 mg/day is recommended in patients with severe renal impairment (creatinine clearance of 5-29 mL/min, based on the Cockcroft-Gault equation).

Forest Pharmaceuticals, Inc.
Subsidiary of Forest Laboratories, Inc.

NXR12339
11/13